Claritev Gelecekteki Büyüme
Future kriter kontrolleri 0/6
Claritev kazanç ve gelirinin sırasıyla yıllık 7.8% ve 3.8% oranında artması tahmin edilirken, EPS'nin yıllık 7.8% oranında büyümesi bekleniyor.
Anahtar bilgiler
7.8%
Kazanç büyüme oranı
7.85%
EPS büyüme oranı
| Healthcare Services kazanç büyümesi | 21.7% |
| Gelir büyüme oranı | 3.8% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 13 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • May 05
CTEV: Volume Resilience And 2026 Buybacks Will Support Future Upside
Claritev's analyst fair value has been revised from $42.75 to $39.80 as analysts factor in slightly lower profit margin assumptions and a small reset in future P/E expectations, in line with recent price target trims from several firms following updated guidance and investment plans. Analyst Commentary Street research on Claritev has shifted toward more conservative assumptions on margin, revenue mix and investment timing, while still highlighting areas where execution could support the current valuation over time.Seeking Alpha • Apr 20
Claritev: Compounding Debt Meets Legacy Business Stabilization (Rating Upgrade)
Summary Claritev is upgraded to 'Hold' after a 32% decline, with the short thesis largely played out. Legacy business revenues are stabilizing, showing 6.2% YoY Q4 growth and accelerating full-year growth, despite margin pressure from regulatory changes. BenInsights' failed pivot is now fully reflected in CTEV’s valuation; any positive developments could act as catalysts. CTEV’s $4.6B debt load and negligible free cash flow keep valuation unattractive, with a 9.2x EV/EBITDA multiple deemed expensive for its risk profile. Read the full article on Seeking AlphaAnlatı Güncellemesi • Apr 20
CTEV: Entrenched Payer Role And 2026 Buyback Capacity Will Support Upside
Claritev's analyst price target has been reset lower, with the model's fair value estimate moving from $44.75 to $42.75 as analysts factor in reduced formal targets from Citi, Guggenheim, and Wells Fargo, along with updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Claritev has coalesced around lower price targets, but the tone is mixed, with analysts highlighting both upside drivers and areas where execution and guidance keep them cautious.
Anlatı Güncellemesi • Apr 05
CTEV: Entrenched Position And Buybacks Will Support Volume Driven Earnings Power
Analysts cut the Claritev price target to $21, with updated models reflecting slightly different revenue growth, profit margin, and future P/E assumptions following recent guidance and sector research. Analyst Commentary Recent Street research on Claritev points to a reset in expectations, with several bearish analysts cutting price targets and highlighting execution and balance sheet risks, even as ratings in the sample remain unchanged.Anlatı Güncellemesi • Mar 22
CTEV: Entrenched Position And Buybacks Will Support More Sustainable Future Margins
Analysts have reduced the Claritev price target to $21 from $33, reflecting updated expectations for slower revenue growth, slightly lower profit margins, and a lower future P/E multiple, even as they cite solid recent results and continued investment in growth initiatives. Analyst Commentary Recent research updates show a clear reset in expectations for Claritev, with multiple firms cutting price targets while generally maintaining existing ratings.Anlatı Güncellemesi • Mar 07
CTEV: Entrenched Payer Role And 2026 Guidance Reset Will Support Upside
The analyst price target for Claritev has been reduced from $57.25 to $44.75. Analysts cited lower revenue growth and profit margin assumptions, as well as a revised future P/E expectation following recent price target cuts from multiple firms.Anlatı Güncellemesi • Feb 21
CTEV: Entrenched Position And Deleveraging Will Support More Sustainable Future Margins
Claritev's analyst price target has been reset lower to $63, down from $80, as analysts factor in a slightly lower future P/E assumption of 9.87x. They also note that the company remains an entrenched vendor with accelerating revenue but elevated leverage that can weigh on valuation.Anlatı Güncellemesi • Feb 06
CTEV: Entrenched Payer Position And Deleveraging Will Support Future Upside
Analysts have trimmed their fair value estimate for Claritev to $57.25 from $85, citing updated Street price targets in the $33 to $63 range and reduced future P/E assumptions, while also acknowledging steady revenue growth and margin expectations. Analyst Commentary Bullish and cautious views on Claritev are both in play, and that split is driving a wide range of price targets and valuation opinions.Anlatı Güncellemesi • Jan 23
CTEV: Revenue Recovery And Deleveraging Will Support More Sustainable Future Margins
Narrative Update Opening Analysts have trimmed their fair value estimate for Claritev from $80 to $33, citing a lower Street price target that ranges from $63 at the high end to $33, and a view that stronger revenue growth and steady margins are now balanced by a less premium future P/E and concerns about elevated leverage. Analyst Commentary Recent research updates on Claritev highlight a split view, with some firms still constructive on the long term while taking down price targets and others starting coverage at more neutral levels.Analiz Makalesi • Jan 18
Claritev Corporation (NYSE:CTEV) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Claritev Corporation ( NYSE:CTEV ) share price has dived 26% in the last...Anlatı Güncellemesi • Jan 09
CTEV: Best In Class Margins And Deleveraging Efforts Will Support Upside
Analysts have raised their average price target on Claritev to US$74 from US$55, citing confidence in the company's ability to accelerate growth while maintaining strong margins, even as some remain cautious about leverage and valuation. Analyst Commentary Recent research paints a mixed picture around Claritev, with bullish analysts highlighting growth potential and margin strength, while more cautious voices focus on balance sheet risk and how much optimism is already reflected in the share price.Anlatı Güncellemesi • Dec 25
CTEV: Mid Single Digit Revenue Recovery Will Support Best In Class Margins
Analysts have raised their price target on Claritev from 55 dollars to 80 dollars, citing increased confidence that the company can reaccelerate to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Recent research notes highlight a more constructive stance on Claritev's long term prospects, with the latest upgrade reflecting greater confidence in management's roadmap to restore sustainable growth while preserving strong profitability.Anlatı Güncellemesi • Dec 11
CTEV: Best-In-Class Margins Will Support Return To Mid-Single-Digit Expansion
Claritev's analyst price target has been raised to $74 from $55, as analysts cite growing confidence that the company can return to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Bullish Takeaways Bullish analysts view the higher $74 target as reflecting renewed confidence in Claritev's ability to reaccelerate revenue growth while preserving margin discipline.Anlatı Güncellemesi • Nov 27
CTEV: Upgraded Buy Rating Will Drive Growth Momentum and Margin Strength
Analysts have raised Claritev’s price target from $80 to $85, reflecting renewed confidence in the company’s accelerating growth and its ability to maintain strong margins. Analyst Commentary Analyst sentiment around Claritev continues to evolve as the company demonstrates a strong execution track record and new growth initiatives.Anlatı Güncellemesi • Nov 06
CTEV: Upgraded Buy Rating Will Drive Renewed Momentum Through 2026
Narrative Update on Claritev Analysts have raised Claritev's price target from $55 to $74, citing increased confidence in the company's plan to accelerate growth and maintain industry-leading margins. Analyst Commentary Following the recent upgrade and price target revision, analysts have shared a range of insights on Claritev’s prospects and execution trajectory.Analiz Makalesi • Nov 01
Improved Revenues Required Before Claritev Corporation (NYSE:CTEV) Stock's 35% Jump Looks Justified
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 35% gain in the last month alone...Anlatı Güncellemesi • Oct 23
Analysts Boost Claritev Valuation Amid Growth Optimism and Strategic Developments
Analysts have raised Claritev's fair value estimate from $70.50 to $80.00. They cite growing confidence in the company's accelerated revenue growth outlook and sustained margins following the recent price target upgrade.Analiz Makalesi • Sep 09
Claritev Corporation's (NYSE:CTEV) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Despite an already strong run, Claritev Corporation ( NYSE:CTEV ) shares have been powering on, with a gain of 27% in...Anlatı Güncellemesi • Aug 08
Digital Transformation And AI Adoption Will Drive Global Healthcare Expansion
Claritev’s future P/E has increased markedly while net profit margin has declined, indicating higher valuation despite weaker profitability, yet the consensus price target remains unchanged at $49.50. What's in the News Claritev updated full-year 2025 revenue guidance to flat to +2% versus 2024.Analiz Makalesi • Jul 30
Claritev (NYSE:CTEV) Use Of Debt Could Be Considered Risky
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jul 09
Claritev Corporation's (NYSE:CTEV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 25% gain in the last month alone...Yeni Anlatı • May 30
AI And Global Partnerships Will Reshape Personalized Medicine
AI-powered analytics, digital transformation, and global expansions position Claritev to monetize higher-value healthcare solutions and tap into growing, aging populations.Analiz Makalesi • May 15
Claritev Corporation (NYSE:CTEV) Shares Fly 30% But Investors Aren't Buying For Growth
Claritev Corporation ( NYSE:CTEV ) shareholders would be excited to see that the share price has had a great month...Analiz Makalesi • Mar 20
Little Excitement Around Claritev Corporation's (NYSE:CTEV) Revenues As Shares Take 28% Pounding
Claritev Corporation ( NYSE:CTEV ) shares have retraced a considerable 28% in the last month, reversing a fair amount...Analiz Makalesi • Feb 03
There's No Escaping MultiPlan Corporation's (NYSE:MPLN) Muted Revenues Despite A 29% Share Price Rise
MultiPlan Corporation ( NYSE:MPLN ) shares have continued their recent momentum with a 29% gain in the last month...Analiz Makalesi • Dec 20
MultiPlan Corporation (NYSE:MPLN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Those holding MultiPlan Corporation ( NYSE:MPLN ) shares would be relieved that the share price has rebounded 28% in...Analiz Makalesi • Dec 13
Here's Why MultiPlan (NYSE:MPLN) Is Weighed Down By Its Debt Load
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Oct 20
MultiPlan Corporation (NYSE:MPLN) Shares Fly 55% But Investors Aren't Buying For Growth
MultiPlan Corporation ( NYSE:MPLN ) shareholders are no doubt pleased to see that the share price has bounced 55% in...Analiz Makalesi • Aug 18
MultiPlan Corporation (NYSE:MPLN) Not Doing Enough For Some Investors As Its Shares Slump 40%
To the annoyance of some shareholders, MultiPlan Corporation ( NYSE:MPLN ) shares are down a considerable 40% in the...Analiz Makalesi • Jul 04
Little Excitement Around MultiPlan Corporation's (NYSE:MPLN) Revenues As Shares Take 46% Pounding
Unfortunately for some shareholders, the MultiPlan Corporation ( NYSE:MPLN ) share price has dived 46% in the last...Analiz Makalesi • Jul 02
MultiPlan (NYSE:MPLN) Use Of Debt Could Be Considered Risky
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • May 09
MultiPlan Corporation (NYSE:MPLN) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the MultiPlan Corporation ( NYSE:MPLN ) share price has dived 29% in the last...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 1,085 | -240 | 71 | 237 | 3 |
| 12/31/2027 | 1,036 | -236 | N/A | 209 | 4 |
| 12/31/2026 | 993 | -273 | 8 | 181 | 3 |
| 3/31/2026 | 979 | -287 | -36 | 102 | N/A |
| 12/31/2025 | 965 | -284 | -12 | 117 | N/A |
| 9/30/2025 | 951 | -342 | -113 | 18 | N/A |
| 6/30/2025 | 936 | -663 | -55 | 71 | N/A |
| 3/31/2025 | 927 | -1,177 | -99 | 28 | N/A |
| 12/31/2024 | 931 | -1,646 | -11 | 108 | N/A |
| 9/30/2024 | 943 | -1,539 | 50 | 169 | N/A |
| 6/30/2024 | 955 | -1,172 | 58 | 168 | N/A |
| 3/31/2024 | 959 | -632 | 41 | 157 | N/A |
| 12/31/2023 | 962 | -92 | 63 | 172 | N/A |
| 9/30/2023 | 958 | -710 | 69 | 172 | N/A |
| 6/30/2023 | 966 | -667 | 107 | 209 | N/A |
| 3/31/2023 | 1,018 | -617 | 153 | 242 | N/A |
| 12/31/2022 | 1,080 | -573 | 283 | 372 | N/A |
| 9/30/2022 | 1,137 | 102 | 286 | 378 | N/A |
| 6/30/2022 | 1,175 | 161 | 345 | 436 | N/A |
| 3/31/2022 | 1,161 | 100 | 338 | 429 | N/A |
| 12/31/2021 | 1,118 | 102 | 320 | 405 | N/A |
| 9/30/2021 | 1,075 | -96 | 338 | 416 | N/A |
| 6/30/2021 | 1,010 | -463 | 317 | 390 | N/A |
| 3/31/2021 | 941 | -472 | 329 | 401 | N/A |
| 12/31/2020 | 938 | -521 | 307 | 377 | N/A |
| 9/30/2020 | 929 | -335 | 281 | 349 | N/A |
| 6/30/2020 | 951 | -42 | 268 | 335 | N/A |
| 3/31/2020 | 990 | 11 | 294 | 361 | N/A |
| 12/31/2019 | 983 | 10 | N/A | 284 | N/A |
| 12/31/2018 | 1,041 | 36 | N/A | 292 | N/A |
| 12/31/2017 | 1,067 | 648 | N/A | 369 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: CTEV önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Kazançlar ve Piyasa: CTEV önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Yüksek Büyüme Kazançları: CTEV önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Gelir ve Pazar: CTEV şirketinin gelirinin (yıllık 3.8% ) US pazarından (yıllık 11.7% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: CTEV şirketinin gelirinin (yıllık 3.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: CTEV 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/21 05:59 |
| Gün Sonu Hisse Fiyatı | 2026/05/21 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Claritev Corporation 8 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Steven Valiquette | Barclays |
| Glen Santangelo | Barclays |
| Andrew D'Silva | B. Riley Securities, Inc. |